( MENAFN - GlobeNewsWire - Nasdaq) Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and expansive market growth. EXTON, PA, June 10, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, is excited to announce its strategic expansion into coverage of the classical hematology market – specifically covering indications such as paroxysmal nocturnal hemoglobinuria (PNH), sickle cell disease, hemolytic anemia, and hemophilia. Classical hematology, addressing the needs of non-malignant hematological disorders, has become an area of rapid evolution.
With multiple product approvals in thrombocytopenia, PNH, hemophilia, sickle-cell disease, and beta-thalassemia in just the past several months, the need for comprehensive market intelligence has never been greater. Spherix's expansion into this high-demand area positions the firm to provide best-in-class support to its clients in navigating the complexities and opportunities across the landscape. “For Spherix, choosing hematology as our seventh core therapeutic coverage area was a straightforward decision,” says Dan Barton, CEO.
“The classic hematology indications are experiencing significant advancements, and it is a sector frequently requested by our clients. We're very excited to announce this expansion and broaden Spher.